Progress in the treatment of localized prostate cancer with external beam irradiation

Tony Y. Eng, Charles Thomas, Terence S. Herman

Research output: Contribution to journalArticle

Abstract

The efficacy of the conventional 2D technique of radiation treatment planning and delivery is limited by toxicity of normal tissue surrounding the target, such that the radiation dose that can be safely delivered to the prostate by external beam radiotherapy cannot exceed 70-72 Gy. Recent technological advances in radiation treatment planning and delivery have allowed higher doses of radiation (>72 Gy) to be safely delivered to the prostate with corresponding improved outcomes. Over the past decades, high-energy (≥4MV) linear accelerators have gradually replaced Cobalt machines in external-beam radiation therapy delivery. 2D radiation therapy treatment systems have changed to 3D conformal radiation therapy and intensity-modulated radiation therapy computed tomography-based systems, allowing tighter tumor margins and decreasing normal tissue toxicities. By switching to computed tomography-based planning, 3D-conformal radiation therapy provides better relative conformality of dose than conventional external beam irradiation therapy. Intensity-modulated radiation therapy has further refined dose conformality by spreading the low-dose region to a larger volume. Parallel with the development and implementation of 3D-conformal radiation therapy and intensity-modulated radiation therapy, improved precision of both target definition and treatment verification can be accomplished by image guidance systems to correct for interfraction and intrafraction movement of the prostate in real time. However, the potential long-term risks of larger volumes of normal tissues receiving low doses of radiation in intensity-modulated radiation therapy are unknown. Particle beam radiation therapy (PBRT) offers unique dose distributions and characteristics with higher relative biological effect and linear energy transfer. PBRT is believed to be more effective in controlling slowly proliferating tumors such as prostate carcinoma. However, the availability of PBRT is limited and the development of economically operable particle beam radiation therapy facilities in the USA is still in progress. Finally, the addition of hormonal therapy to radiation therapy has been shown to improve outcome in selected patients. Androgen deprivation causes cytoreduction of the prostate cancer (smaller volume treated to high doses), better local control and disease-free survival. Long-term adjuvant androgen deprivation has also been shown to improve overall survival, especially in more advanced tumors.

Original languageEnglish (US)
Pages (from-to)93-108
Number of pages16
JournalExpert Review of Anticancer Therapy
Volume6
Issue number1
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Radiotherapy
Therapeutics
Radiation
Prostate
Androgens
Tomography
Linear Energy Transfer
Neoplasms
Particle Accelerators
Cobalt
Disease-Free Survival
Carcinoma

Keywords

  • 3D conformal radiation therapy
  • Conventional external beam radiation therapy
  • Hormonal therapy
  • Intensity modulated radiation therapy
  • Particle beam radiation therapy
  • Prostate cancer
  • Toxicity

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

Progress in the treatment of localized prostate cancer with external beam irradiation. / Eng, Tony Y.; Thomas, Charles; Herman, Terence S.

In: Expert Review of Anticancer Therapy, Vol. 6, No. 1, 2006, p. 93-108.

Research output: Contribution to journalArticle

@article{01be7566b58043ef8eef679b348390d9,
title = "Progress in the treatment of localized prostate cancer with external beam irradiation",
abstract = "The efficacy of the conventional 2D technique of radiation treatment planning and delivery is limited by toxicity of normal tissue surrounding the target, such that the radiation dose that can be safely delivered to the prostate by external beam radiotherapy cannot exceed 70-72 Gy. Recent technological advances in radiation treatment planning and delivery have allowed higher doses of radiation (>72 Gy) to be safely delivered to the prostate with corresponding improved outcomes. Over the past decades, high-energy (≥4MV) linear accelerators have gradually replaced Cobalt machines in external-beam radiation therapy delivery. 2D radiation therapy treatment systems have changed to 3D conformal radiation therapy and intensity-modulated radiation therapy computed tomography-based systems, allowing tighter tumor margins and decreasing normal tissue toxicities. By switching to computed tomography-based planning, 3D-conformal radiation therapy provides better relative conformality of dose than conventional external beam irradiation therapy. Intensity-modulated radiation therapy has further refined dose conformality by spreading the low-dose region to a larger volume. Parallel with the development and implementation of 3D-conformal radiation therapy and intensity-modulated radiation therapy, improved precision of both target definition and treatment verification can be accomplished by image guidance systems to correct for interfraction and intrafraction movement of the prostate in real time. However, the potential long-term risks of larger volumes of normal tissues receiving low doses of radiation in intensity-modulated radiation therapy are unknown. Particle beam radiation therapy (PBRT) offers unique dose distributions and characteristics with higher relative biological effect and linear energy transfer. PBRT is believed to be more effective in controlling slowly proliferating tumors such as prostate carcinoma. However, the availability of PBRT is limited and the development of economically operable particle beam radiation therapy facilities in the USA is still in progress. Finally, the addition of hormonal therapy to radiation therapy has been shown to improve outcome in selected patients. Androgen deprivation causes cytoreduction of the prostate cancer (smaller volume treated to high doses), better local control and disease-free survival. Long-term adjuvant androgen deprivation has also been shown to improve overall survival, especially in more advanced tumors.",
keywords = "3D conformal radiation therapy, Conventional external beam radiation therapy, Hormonal therapy, Intensity modulated radiation therapy, Particle beam radiation therapy, Prostate cancer, Toxicity",
author = "Eng, {Tony Y.} and Charles Thomas and Herman, {Terence S.}",
year = "2006",
doi = "10.1586/14737140.6.1.93",
language = "English (US)",
volume = "6",
pages = "93--108",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Progress in the treatment of localized prostate cancer with external beam irradiation

AU - Eng, Tony Y.

AU - Thomas, Charles

AU - Herman, Terence S.

PY - 2006

Y1 - 2006

N2 - The efficacy of the conventional 2D technique of radiation treatment planning and delivery is limited by toxicity of normal tissue surrounding the target, such that the radiation dose that can be safely delivered to the prostate by external beam radiotherapy cannot exceed 70-72 Gy. Recent technological advances in radiation treatment planning and delivery have allowed higher doses of radiation (>72 Gy) to be safely delivered to the prostate with corresponding improved outcomes. Over the past decades, high-energy (≥4MV) linear accelerators have gradually replaced Cobalt machines in external-beam radiation therapy delivery. 2D radiation therapy treatment systems have changed to 3D conformal radiation therapy and intensity-modulated radiation therapy computed tomography-based systems, allowing tighter tumor margins and decreasing normal tissue toxicities. By switching to computed tomography-based planning, 3D-conformal radiation therapy provides better relative conformality of dose than conventional external beam irradiation therapy. Intensity-modulated radiation therapy has further refined dose conformality by spreading the low-dose region to a larger volume. Parallel with the development and implementation of 3D-conformal radiation therapy and intensity-modulated radiation therapy, improved precision of both target definition and treatment verification can be accomplished by image guidance systems to correct for interfraction and intrafraction movement of the prostate in real time. However, the potential long-term risks of larger volumes of normal tissues receiving low doses of radiation in intensity-modulated radiation therapy are unknown. Particle beam radiation therapy (PBRT) offers unique dose distributions and characteristics with higher relative biological effect and linear energy transfer. PBRT is believed to be more effective in controlling slowly proliferating tumors such as prostate carcinoma. However, the availability of PBRT is limited and the development of economically operable particle beam radiation therapy facilities in the USA is still in progress. Finally, the addition of hormonal therapy to radiation therapy has been shown to improve outcome in selected patients. Androgen deprivation causes cytoreduction of the prostate cancer (smaller volume treated to high doses), better local control and disease-free survival. Long-term adjuvant androgen deprivation has also been shown to improve overall survival, especially in more advanced tumors.

AB - The efficacy of the conventional 2D technique of radiation treatment planning and delivery is limited by toxicity of normal tissue surrounding the target, such that the radiation dose that can be safely delivered to the prostate by external beam radiotherapy cannot exceed 70-72 Gy. Recent technological advances in radiation treatment planning and delivery have allowed higher doses of radiation (>72 Gy) to be safely delivered to the prostate with corresponding improved outcomes. Over the past decades, high-energy (≥4MV) linear accelerators have gradually replaced Cobalt machines in external-beam radiation therapy delivery. 2D radiation therapy treatment systems have changed to 3D conformal radiation therapy and intensity-modulated radiation therapy computed tomography-based systems, allowing tighter tumor margins and decreasing normal tissue toxicities. By switching to computed tomography-based planning, 3D-conformal radiation therapy provides better relative conformality of dose than conventional external beam irradiation therapy. Intensity-modulated radiation therapy has further refined dose conformality by spreading the low-dose region to a larger volume. Parallel with the development and implementation of 3D-conformal radiation therapy and intensity-modulated radiation therapy, improved precision of both target definition and treatment verification can be accomplished by image guidance systems to correct for interfraction and intrafraction movement of the prostate in real time. However, the potential long-term risks of larger volumes of normal tissues receiving low doses of radiation in intensity-modulated radiation therapy are unknown. Particle beam radiation therapy (PBRT) offers unique dose distributions and characteristics with higher relative biological effect and linear energy transfer. PBRT is believed to be more effective in controlling slowly proliferating tumors such as prostate carcinoma. However, the availability of PBRT is limited and the development of economically operable particle beam radiation therapy facilities in the USA is still in progress. Finally, the addition of hormonal therapy to radiation therapy has been shown to improve outcome in selected patients. Androgen deprivation causes cytoreduction of the prostate cancer (smaller volume treated to high doses), better local control and disease-free survival. Long-term adjuvant androgen deprivation has also been shown to improve overall survival, especially in more advanced tumors.

KW - 3D conformal radiation therapy

KW - Conventional external beam radiation therapy

KW - Hormonal therapy

KW - Intensity modulated radiation therapy

KW - Particle beam radiation therapy

KW - Prostate cancer

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=33645651281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645651281&partnerID=8YFLogxK

U2 - 10.1586/14737140.6.1.93

DO - 10.1586/14737140.6.1.93

M3 - Article

AN - SCOPUS:33645651281

VL - 6

SP - 93

EP - 108

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 1

ER -